TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Spero Therapeutics ( (SPRO) ) has provided an update.
On November 13, 2025, Spero Therapeutics announced its third-quarter financial results and provided a business update. The company highlighted the Phase 3 PIVOT-PO trial results for tebipenem HBr, an investigational oral antibiotic for complicated urinary tract infections, which demonstrated non-inferiority to intravenous treatments. Spero’s partner, GSK, plans to submit these results to the FDA in the fourth quarter of 2025. The company reported a net loss of $7.4 million for the third quarter of 2025, a decrease from the previous year, and expects its current cash reserves to fund operations into 2028.
The most recent analyst rating on (SPRO) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Spero Therapeutics stock, see the SPRO Stock Forecast page.
Spark’s Take on SPRO Stock
According to Spark, TipRanks’ AI Analyst, SPRO is a Neutral.
Spero Therapeutics is currently facing significant financial and operational challenges, as evidenced by declining revenues, negative profit margins, and operational inefficiencies. Technical analysis suggests ongoing bearish momentum, while valuation metrics highlight financial struggles due to a negative P/E ratio. The earnings call highlighted promising developments in their tebipenem HBr program, but these are offset by setbacks in other trials and increased financial losses. The overall score reflects these mixed but predominantly negative factors.
To see Spark’s full report on SPRO stock, click here.
More about Spero Therapeutics
Spero Therapeutics, based in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company specializing in the development of novel treatments for rare diseases and multi-drug resistant bacterial infections.
Average Trading Volume: 643,076
Technical Sentiment Signal: Buy
Current Market Cap: $149.7M
Learn more about SPRO stock on TipRanks’ Stock Analysis page.